The European Commission has approved the marketing authorisation variation of Boehringer Ingelheim’s PCV2 vaccine Ingelvac CircoFLEX. This approval allows the combined use of the pig vaccines Ingelvac CircoFLEX and Ingelvac MycoFLEX in the EU.

The European Commission has approved the marketing authorisation variation of Boehringer Ingelheim’s PCV2 vaccine Ingelvac CircoFLEX. This approval allows the combined use of the pig vaccines Ingelvac CircoFLEX and Ingelvac MycoFLEX in the EU.

Boehringer Ingelheim will market the vaccine concept under the name FLEXcombo. Now protection against two of the most prominent and costly pig diseases, porcine circovirus disease (PCVD) and enzootic pneumonia, can be achieved with a single injection instead of up to four injections. More than 70% of European pigs are currently vaccinated against both these diseases.

The combined use of Ingelvac CircoFLEX and Ingelvac MycoFLEX is already registered and widely used in North America and Asia. It is globally the first and only product combination of its kind. “We are very proud, that we can now also supply EU veterinarians and farmers with this latest innovation that will help tremendously in reducing the number of injections to pigs, supporting the well-being of the animals and the farm economics by saving a substantial amount of labour,” said Joachim Hasenmaier, global head of animal health for Boehringer Ingelheim.

View your activity >

Leave a Reply

Be the First to Comment!

Notify of
avatar

wpDiscuz